Literature DB >> 8667045

Diminished glucose transport and phosphorylation in Alzheimer's disease determined by dynamic FDG-PET.

M Piert1, R A Koeppe, B Giordani, S Berent, D E Kuhl.   

Abstract

UNLABELLED: Using dynamic [18F]fluorodeoxyglucose (FDG) and PET, kinetic rate constants that describe influx (K1) and efflux (k2) of FDG as well as phosphorylation (k3) and dephosphorylation (k4) were determined in patients with probable Alzheimer's disease and similarly aged normal controls.
METHODS: The regional cerebral metabolic rate for glucose (CMRglu) was calculated from individually fitted rate constants in frontal, temporal, parietal and occipital cerebral cortex, caudate nucleus, putamen, thalamus and cerebellar cortex. Dynamic PET scans were obtained in normal controls (n = 10, mean age = 67) and Alzheimer's disease patients (n = 8, mean age = 67) for 60 min following injection of 10 mCi of FDG.
RESULTS: The Alzheimer's disease group was characterized by decreases of the CMRglu ranging from 13.3% in the frontal to 40.9% in the parietal cortex, which achieved significance in all regions except the thalamus. K1 was significantly reduced in the parietal (p < 0.01) and temporal cortices (p < 0.05). Significant declines in k3 were found in the parietal (p < 0.005), temporal and occipital cortex, and in the putamen and cerebellum (p < 0.05). The rate constants k2 and k4 were unchanged in the Alzheimer's disease group.
CONCLUSION: These data suggest that hypometabolism in Alzheimer's disease is related to reduced glucose phosphorylation activity as well as diminished glucose transport, particularly in the most metabolically affected areas of the brain, the parietal and temporal cortex.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8667045

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  42 in total

1.  Diagnosis of suspected Alzheimer's disease is improved by automated analysis of regional cerebral blood flow.

Authors:  Bich-Ngoc-Thanh Tang; Satoshi Minoshima; Jean George; Annie Robert; Christian Swine; Patrice Laloux; Thierry Vander Borght
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-01       Impact factor: 9.236

Review 2.  Glucose Transporters at the Blood-Brain Barrier: Function, Regulation and Gateways for Drug Delivery.

Authors:  Simon G Patching
Journal:  Mol Neurobiol       Date:  2016-01-22       Impact factor: 5.590

3.  Quantitation, regional vulnerability, and kinetic modeling of brain glucose metabolism in mild Alzheimer's disease.

Authors:  Lisa Mosconi; Wai H Tsui; Henry Rusinek; Susan De Santi; Yi Li; Gene-Jack Wang; Alberto Pupi; Joanna Fowler; Mony J de Leon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-04-04       Impact factor: 9.236

4.  Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons.

Authors:  Winnie S Liang; Eric M Reiman; Jon Valla; Travis Dunckley; Thomas G Beach; Andrew Grover; Tracey L Niedzielko; Lonnie E Schneider; Diego Mastroeni; Richard Caselli; Walter Kukull; John C Morris; Christine M Hulette; Donald Schmechel; Joseph Rogers; Dietrich A Stephan
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-10       Impact factor: 11.205

5.  Association between FDG uptake, CSF biomarkers and cognitive performance in patients with probable Alzheimer's disease.

Authors:  Sönke Arlt; Stefanie Brassen; Holger Jahn; Florian Wilke; Martin Eichenlaub; Ivayla Apostolova; Fabian Wenzel; Frank Thiele; Stewart Young; Ralph Buchert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-02-14       Impact factor: 9.236

6.  Genetic association of SLC2A14 polymorphism with Alzheimer's disease in a Han Chinese population.

Authors:  Wei Wang; Jin-Tai Yu; Wei Zhang; Wei-Zhen Cui; Zhong-Chen Wu; Qun Zhang; Lan Tan
Journal:  J Mol Neurosci       Date:  2012-03-16       Impact factor: 3.444

Review 7.  Drug access to the central nervous system in Alzheimer's disease: preclinical and clinical insights.

Authors:  Dharmini C Mehta; Jennifer L Short; Sarah N Hilmer; Joseph A Nicolazzo
Journal:  Pharm Res       Date:  2014-10-16       Impact factor: 4.200

8.  Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia.

Authors:  Eric M Reiman; Kewei Chen; Gene E Alexander; Richard J Caselli; Daniel Bandy; David Osborne; Ann M Saunders; John Hardy
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-19       Impact factor: 11.205

Review 9.  Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease.

Authors:  Lisa Mosconi; Alberto Pupi; Mony J De Leon
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

Review 10.  Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders.

Authors:  Melanie D Sweeney; Abhay P Sagare; Berislav V Zlokovic
Journal:  Nat Rev Neurol       Date:  2018-01-29       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.